降低日本心力衰竭负担使用达帕格利弗洛辛 - 一个成本抵消模型 (IMPLICATION HF)
Takuya Kishi1, Eriko Kunikane2, Hiroyuki Takagi2
1Department of Graduate School of Medicine (Cardiology), International University of Health and Welfare Fukuoka Japan.
Circulation reports
|June 11, 2025
概括
预计日本的达帕格利弗洛辛使用将显著减少心力衰竭事件和相关的医疗保健成本. 这种SGLT2抑制剂通过预防心力衰竭患者住院和死亡,为经济带来了巨大的好处.
科学领域:
- 心血管医学 心血管医学
- 卫生经济学 卫生经济学
- 药物经济学 药物经济学
背景情况:
- 达帕格利弗洛辛在心力衰竭 (HF) 中显示出临床益处.
- 达帕格利弗洛辛对降低日本高温热负担的经济影响尚不清楚.
- 实施HF研究旨在使用成本抵消模型来预测这些减少.
研究的目的:
- 预测日本使用达帕格利弗洛辛的HF事件和相关成本的减少.
- 量化大帕格利弗洛辛在日本高温肺炎患者群体中的经济益处.
- 评估预防HF住院和死亡的成本抵消.
主要方法:
- 从DAPA-HF和DELIVER试验中建模了症状性HF患者.
- 从已发表的文献中利用了日本HF的流行率,事件率和成本.
- 从一个聚合的元分析中应用达帕格利弗洛辛治疗效应,以估计使用和不使用药物的事件发生率和成本.
主要成果:
- 预计在一年内预防63,770例高风险住院 (NNT 20),11,613例心血管死亡 (NNT 108) 和16,141例因任何原因死亡.
- 预计将减少627亿日元的HF住院费用和166亿日元的CV死亡费用.
- 在日本,每年总计预计成本抵消为793亿日元.
结论:
- 据预计,除了治疗HF,Dapagliflozin还将为日本医疗保健系统带来显著的经济效益.
- 这一发现支持了大帕格利弗洛辛在日本治疗心力衰竭的成本效益.
- 这项研究强调了SGLT2抑制剂在高风险患者中降低临床事件和医疗保健支出的潜力.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
396
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
396
01:22Heart Failure Drugs: Diuretics
349
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
349
01:22Heart Failure Drugs: β-Blockers
320
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
320
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:26Heart Failure Drugs: Inotropic Agents
539
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
539
01:26Imbalances in Cardiac Output
1.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K